Efficacy and safety of olokizumab in the treatment of rheumatoid arthritis in real clinical practice in Kazakhstan
Abstract
Objective: Olokizumab (OKZ) is one of the innovative biologic treatments for rheumatoid arthritis (RA) targeting interleukin-6 (IL-6). The study purpose was to evaluate the 24-week efficacy and safety of OKZ in routine clinical practice among RA patients in Kazakhstan, filling a gap in existing research focusing on Western populations.
Materials and methods: A 24-week, single-center, observational study. A total of 26 RA patients with moderate to high disease activity (by DAS28) despite methotrexate therapy received olokizumab 64 mg subcutaneously (every 4 weeks) combined with methotrexate. Disease activity (DAS28-CRP) was evaluated at baseline, at week 4, week 12 and at week 24.
Results and discussion: 88% of patients were female, all were seropositive with median age of 53 years (range 24–73), and mean DAS28-CRP 5.5 ± 1.3. At week 24, a EULAR good and moderate response was observed in 19 (73.0%) patients. Significant improvements were noted from baseline DAS28-CRP by week 12 and week 24 (p<0.05). Remission rate (based on DAS28-CRP) was 50.0% (figure 2). Olokizumab was generally well tolerated, with no unexpected safety findings.
Conclusion: This real-world study confirmed efficacy and safety of olokizumab in line with previous RCT results in a predominantly Asian RA population, supporting its adoption in routine clinical management of RA as an effective and well-tolerated treatment option.
About the Authors
G. A. Togizbayev
Republic Rheumatology Center of JSC "Research Institute of Cardiology and Internal Diseases, Kazakh National Medical University named after S.D. Asfendiyarov (KazNMU)
Kazakhstan
Kazakhstan
Almaty, Ayteke Biy Street 120
D. I. Parpiyeva
Kazakh National Medical University named after S.D. Asfendiyarov (KazNMU)
Kazakhstan
Kazakhstan
Almaty, Töle Biy Street, 94
D. A. Maksot
Kazakh National Medical University named after S.D. Asfendiyarov (KazNMU)
Kazakhstan
Kazakhstan
Almaty, Töle Biy Street, 94
References
1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-2038.
2. Chen, Y.-C.; Huang, C.-M.; Liu, T.-Y.; Wu, N.; Chan, C.-J.; Shih, P.-Y.; Chen, H.-H.; Chen, S.-Y.; Tsai, F.-J. Effects of Human Leukocyte Antigen DRB1 Genetic Polymorphism on Anti-Cyclic Citrullinated Peptide (ANTI-CCP) and Rheumatoid Factor (RF) Expression in Rheumatoid Arthritis (RA) Patients. Int. J. Mol. Sci. 2023, 24, 12036. https://doi.org/10.3390/ijms241512036.
3. Prasad P, Kumar A, Gupta R, Juyal RC, Thelma BK. Caucasian and Asian specific rheumatoid arthritis risk loci reveal limited replication and apparent allelic heterogeneity in north Indians. PLoS One. 2012;7(2):e31584. doi: 10.1371/journal.pone.0031584. Epub 2012 Feb 15. PMID: 22355377; PMCID: PMC3280307.
4. Felson DT. Comparing the prevalence of rheumatic diseases in China with the rest of the world. Arthritis Res Ther. 2008;10(1):106. doi: 10.1186/ar2369. Epub 2008 Feb 25. PMID: 18341701; PMCID: PMC2374465.
5. Suenaga, Y., Yasuda, M., Zhao, Y. et al. Rheumatoid arthritis in the Northeastern area of the People's Republic of China and Western Japan. Clin Rheumatol 14, 76–80 (1995). https://doi.org/10.1007/BF02208088
6. Baek HJ, Lim MJ, Park W, Park SH, Shim SC, Yoo DH, Kim HA, Lee SK, Lee YJ, Park YE, Cha HS, Song YW. Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis. Korean J Intern Med. 2019 Jul;34(4):917-931. doi: 10.3904/kjim.2017.159. Epub 2018 Jan 17. PMID: 29334721; PMCID: PMC6610180.
7. Jinno, S., Onishi, A., Dubreuil, M. et al. Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis—the ANSWER cohort study. Arthritis Res Ther 23, 116 (2021). https://doi.org/10.1186/s13075-021-02496-w
8. Karateyev D.E. MD, PhD, Prof., E.L. Luchikhina, PhD. Interleukin 6 Inhibitors in the Treatment of Rheumatoid Arthritis. Effectivnaya pharmacoterapiya = Effective pharmacotherapy. 2022; 18 (8): 16–21. (In Russ.) DOI 10.33978/2307-3586-2022-18-8-16-21.
9. Smolen JS, Feist E, Fatenejad S, Grishin SA, Korneva EV, Nasonov EL, Samsonov MY, Fleischmann RM; CREDO2 Group. Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2022 Aug 25;387(8):715-726. doi: 10.1056/NEJMoa2201302. PMID: 36001712.
10. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S93-S99.
11. Baimukhamedov C, Togizbayev G, Mirakhmedova K, Mamasaidov A, Shukurova S. Increasing autoimmune rheumatic diseases as a consequence of the COVID-19 pandemic: A hypothesis or fact? Int J Rheum Dis. 2024 Jan;27(1):e15011. doi: 10.1111/1756-185X.15011. Epub 2023 Dec 22
12. Tsutomu Takeuchi, Yoshiya Tanaka, Hisashi Yamanaka, Kanzo Amano,Ryuji Nagamine, Won Park, Kazuko Shiozawa, Michishi Tsukano, James Cheng-Chung Wei, Jing Shao, Osamu Togo & Hideki Mashimo (2016) Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial, Modern Rheumatology, 26:1, 15-23, DOI:10.3109/14397595.2015.1074648.
Review
For citations:
Togizbayev GA, Parpiyeva DI, Maksot DA. Efficacy and safety of olokizumab in the treatment of rheumatoid arthritis in real clinical practice in Kazakhstan. Sovremennaya Revmatologiya=Modern Rheumatology Journal. (In Russ.)
Views:
116
Email this article 